Ivabradina Vir

Ivabradine, the active ingredient in Ivabradina Vir, is an If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is employed in chronic stable angina and heart failure in appropriate patients.

GNH USA supplies Ivabradina Vir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradina Vir (ivabradine) is used in cardiovascular conditions that involve elevated heart rate. - Chronic stable angina: lowers heart rate to reduce frequency of angina episodes. - Heart failure (NYHA class II‑III): improves symptoms and may decrease hospitalisation by controlling heart rate.

Ivabradina Vir may cause a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects: - Bradycardia: resting heart rate may fall below 50 bpm. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects: - Symptomatic bradycardia: may cause syncope or fatigue. - Atrial fibrillation: irregular heart rhythm requiring medical attention. - Severe visual impairment: persistent blurred vision or colour disturbances. - Hepatic enzyme elevation: significant increase in liver transaminases.

Before prescribing Ivabradina Vir, clinicians should observe the following precautions. - Baseline heart rate assessment: ensure resting HR ≥ 50 bpm before initiation. - Acute decompensated heart failure: avoid use in patients with worsening symptoms. - Concomitant CYP3A4 inhibitors: use caution as they can raise ivabradine plasma levels. - Monitoring for bradycardia: regularly check pulse and symptoms of dizziness. - Visual disturbances: discontinue if persistent or severe visual symptoms occur. - Store at room temperature: keep in the original container, protect from moisture and light.

Ivabradina Vir interacts with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): markedly increase ivabradine exposure. - Co‑administration with other heart‑rate‑lowering agents (beta‑blockers, digoxin): risk of excessive bradycardia. - Verapamil: potent CYP3A4 inhibition leading to elevated drug levels.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., diltiazem, fluconazole): may require dose adjustment. - QT‑prolonging drugs (e.g., certain antiarrhythmics): increase risk of cardiac arrhythmias. - Smoking: induces CYP3A4 and can reduce ivabradine effectiveness.